Skip to main content
SpringerLink
Log in
Book cover

Angiotensin and the Heart pp 43–64Cite as

ACE-inhibitors in coronary artery disease?

  • Chapter

  • 76 Accesses

Summary

Angiotensin converting enzyme (ACE)-inhibitors are established in the treatment of arterial hypertension and heart failure. In recent years ACE-inhibitors have also been used in the treatment of patients with coronary artery disease (CAD), since from experimental data an antiischemic action of these agents is suggested. Antiischemic effects of ACE-inhibitors may be exerted through a reduction of myocardial oxygen demand, by a reduction of angiotensin-mediated coronary vasoconstriction, by an interaction with bradykinin and the prostaglandin system, by a modulation of endothelial control of vascular tone, and by an interaction with the sympathetic nervous system. However, clinical findings on potential beneficial effects of ACE-inhibitors in patients with CAD are inconsistent and controversial. While in hypertensive patients with CAD ACE-inhibitors generally seem to attenuate myocardial ischemia at rest and during exercise, a significant fraction of about 30% of normotensive patients with CAD does not benefit or even deteriorates. Lowering of coronary perfusion pressure and alteration of transmural blood flow distribution may be responsible for this. In patients with left ventricular dysfunction (SOLVD) or congestive heart failure (CONSENSUS, SOLVD) ACE-inhibitors have been proven to prevent progressive deterioration in left ventricular function and to reduce mortality. In patients with asymptomatic left ventricular dysfunction after myocardial infarction (SAVE), long-term administration of captropril was associated with an improvement in survival and reduced morbidity and mortality due to major cardiovascular events. Therefore, from a prognostic viewpoint patients with CAD and left ventricular dysfunction or congestive heart failure should be treated with ACE-inhibitors, although the clinical use of ACE-inhibitors in patients with ongoing angina pectoris may be limited by an aggravation of angina, presumably due to critically lowering coronary perfusion pressure. Finally, ACE-inhibitors failed to prevent restenosis after successful PTCA. In conclusion, from a prognostic viewpoint patients with CAD and congestive heart failure or left ventricular dysfunction should be treated with ACE-inhibitors. In hypertensive patients ACE-inhibitors generally seem to attenuate myocardial ischemia. In normotensive patients with CAD and angina pectoris but without left ventricular dysfunction ACE-inhibitors cannot generally be recommended at present, unless the patients, which may have benefit from ACE-inhibitor treatment can be better defined.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aiken JW, Reit E (1968) Stimulation of the cat stellate ganglion by angiotensin. J Pharmacol Exp Ther 159: 107–114

    PubMed  CAS  Google Scholar 

  2. Akhras F, Jackson G (1991) The role of Captopril as single therapy in hypertension and angina pectoris. Int J Cardiol. 33: 259–266

    Article  PubMed  CAS  Google Scholar 

  3. Alderman EL, Fisher LD, Litwin P (1983) Results of coronary artery surgery in patients with poor left ventricular function ( CLASS ). Circulation 68: 785–795

    Google Scholar 

  4. Auch-Schwelk W, Bossaller C, Claus M, Graf K, Gräfe M, Schüler S, Fleck E (1992) Mechanismus der Bradykinin-vermittelten vasodilatierenden Wirkung von ACE-Inhibitoren in Koronararterien. Z Kardiol 81 (suppl 1): 112

    Google Scholar 

  5. Berdeaux A, Bonhenry C, Giudicelli JF (1987) Effects of four angiotensin I converting enzyme inhibitors on regional myocardial blood flow and ischemic injury during coronary artery occlusion in dogs. Fundam Clin Pharmacol 1: 201–208

    Article  PubMed  CAS  Google Scholar 

  6. Berger HJ, Zaret BJ, Speroff L (1977) Cardiac prostaglandin release during myocardial ischemia induced by atrial pacing in patients with coronary artery disease. Am J Cardiol 39: 481–486

    Article  PubMed  CAS  Google Scholar 

  7. Bianchi A, de Schaepdryver AF, de Vleeschhouwer GR, Preziosi P (1960) On the pharmacology of synthetic hypertensine. Arch Int Pharmacodyn Ther 124: 21–44

    PubMed  CAS  Google Scholar 

  8. Boadle MC, Hughes J, Roth RH (1969) Angiotensin accelerates catecholamine biosynthesis in sympathetically innervated tissues. Nature 222: 987–988

    Article  PubMed  CAS  Google Scholar 

  9. Blumberg AL, Ackerly JA, Peach MJ (1976) Differentiation of neurogenic and myocardial angiotensin II receptors in isolated rabbit atria. Circ Res 36: 719–726

    Google Scholar 

  10. Bossaller C, Auch-Schwelk W, Götze S, Weber F, Graf K, Gräfe M, Hehlert-Friedrich C, Fleck E (1992) Die chronische Behandlung mit Enalapril fuhrt zu einer Zunahme der endothelabhängigen Relaxation. Z Kardiol 81 (suppl 1): 29

    Google Scholar 

  11. Brivet F, Deltraissy JF, Gindicelly JF, Richer C, Legrand A, Dormont J (1981) Immediate effects of Captopril in acute left ventricular failure secondary to myocardial infarction. Eur J Clin Invest 11: 369–374

    Article  PubMed  CAS  Google Scholar 

  12. Bush LR, Campbell WB, Kern K (1984) The effects of alpha2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res 55: 642–648

    PubMed  CAS  Google Scholar 

  13. Bussmann WD, Goerke S, Schneider W, Kaltenbach M (1988) Angiotensin-con- verting-Enzym-Hemmer bei Angina pectoris. Dtsch Med Wochenschr 113: 548–550

    Article  PubMed  CAS  Google Scholar 

  14. Campbell DJ, Habener JF (1987) Cellular localization of angiotensin gene expression in brown and adipose tissue and mesentery: Quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology 121: 1616–1626

    Google Scholar 

  15. Chatterjee K, Rouleau J-L, Parmely WW (1982) Haemodynamic and myocardial metabolic effects of Captopril in chronic heart failure. Br Heart J 47: 233–238

    Article  PubMed  CAS  Google Scholar 

  16. Chatterjee K, Opie LH (1987) Angiotensin inhibitors and other vasodilators with special reference to congestive heart failure. Cardiovasc Drugs Ther 1: 1–8

    Article  PubMed  CAS  Google Scholar 

  17. Chu A, Morris K, Kuehl WD (1989) Effects of atrial natriuretic peptide on the coronary arterial vasculature in humans. Circulation 80: 1627–1632

    Article  PubMed  CAS  Google Scholar 

  18. Cleland JGF, Dargie HJ, Hodsman GP (1984) Captopril in heart failure. A double blind controlled trial. Br Heart J 52: 530–535

    Google Scholar 

  19. Cleland JGF, Dargie HJ, Ball SG (1985) Effects of enalapril in heart failure: a double- blind study of effects on exercise performance, renal function, hormones and metabolic state. Br Heart J 54: 305–312

    Article  PubMed  CAS  Google Scholar 

  20. Cleland JG, Henderson E, McLenachan J, Findlay TN, Dargie HJ (1991) Effect of Captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol 17: 733–739

    Article  PubMed  CAS  Google Scholar 

  21. Clough DP, Mulroy SC, Angell D, Hatton R (1983) Inference by inhibitors of the renin- angiotensin system with neurogenic vasoconstriction. Clin Exp Hypertens 5: 1287–1291

    Article  CAS  Google Scholar 

  22. Cohen MV, Kirk ES (1973) Differential response of large and small coronary arteries to nitroglycerin and angiotensin. Circ Res 33: 445–453

    PubMed  CAS  Google Scholar 

  23. Cohn JN (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl J Med 325: 303–308

    Article  PubMed  CAS  Google Scholar 

  24. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med 316: 1429–1435

    Article  Google Scholar 

  25. Daly P, Rouleau JL, Cousineau D, Burgess JH (1984) Acute effects of Captopril on the coronary circulation of patients with hypertension and angina. Am J Med 31: 111–115

    Article  Google Scholar 

  26. Daly P, Mettauer B, Rouleau JL, Burgess J (1985) Lack of reflex increase in myocardial sympathetic tone after Captopril: Potential antianginal effect. Circulation 71: 317–325

    Google Scholar 

  27. Dargie HJ, McAlpine HM, Morton JJ (1987) Neuroendocrine activation in acute myocardial infarction. J Cardiovasc Pharmacol 9 (suppl 2): S21–S24

    Article  PubMed  CAS  Google Scholar 

  28. Day MD, Moore AF (1976) Interaction of angiotensin II with noradrenaline and other spasmogens in rabbit isolated aortic strips. Arch Int Pharmacodyn Ther 219: 29–44

    PubMed  CAS  Google Scholar 

  29. De Graeff PA, van Gilst WH, de Langen CD J (1986) Concentration-dependent protection by Captopril against ischemia-reperfusion injury in the isolated rat heart. Arch Int Pharmacodyn 280: 181–193

    Google Scholar 

  30. De Jonge A, Wilffert B, Kalkman HO (1981) Captopril impairs the vascular smooth muscle contraction mediated by postsynaptic alpha2-adrenoceptors in the pithed rat. Eur J Pharmacol 74: 385–386

    Article  PubMed  Google Scholar 

  31. De Jonge A, Thoolen MJ, Timmermans PB (1984) Interaction of angiotensin converting enzyme inhibitors with the sympathetic nervous system. Prog Pharmacol 5 /3: 25–38

    Google Scholar 

  32. Detre K, Holubkov R, Kelsey S, Cowley M, et al. (1988) Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981: The National Heart, Lung, Blood Institute Registry. N Engl J Med 318: 265–270

    Google Scholar 

  33. Dinerman JL, Mehta JL (1990) Endothelial, platelet and leukocyte interactions in ischemic heart disease: Insights into potential mechanism and their clinical relevance. J Am Coll Cardiol 16: 207–211

    Google Scholar 

  34. Drimal J, Boska D (1973) Effects of angiotensin II on myocardial mechanics and contractile state of the heart muscle. Eur J Pharmacol 20: 130–138

    Article  Google Scholar 

  35. Dunn WR, McGrath JC, Wilson VG (1989) Expression of functional postjunctional alpha2-adrenoceptor in rabbit isolated distal saphenous artery-a permissive role for angiotensin II? Br J Pharmacol 96: 259–261

    PubMed  CAS  Google Scholar 

  36. Dzau VJ (1987) Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol 59: 59A–65A

    Article  PubMed  CAS  Google Scholar 

  37. Dzau VJ (1988) Circulating versus local-angiotensin system in cardiovascular homeostasis. Circulation 77 (suppl I): 14–113

    Article  Google Scholar 

  38. Dzau VJ (1989) ACE-inhibitors in hypertension: A US perspective. Cardiology 76 (suppl 2): 23–30

    Article  PubMed  Google Scholar 

  39. Eaton LW, Weiss JL, Bulkley BH, Garrison JB, Weisfeldt ML (1979) Regional cardiac dilatation after acute myocardial infarction: recognition by two-dimensional echocardiography. N Engl J Med 300: 57–62

    Article  PubMed  CAS  Google Scholar 

  40. Ertl G, Gerhards W, Wichmann J, Fauth S, Schweisfurth H (1982) Myokardischämie, Plasma-Renin und Converting-Enzym-Aktivität unter Belastung. Z Kardiol 71: 604–611

    Google Scholar 

  41. Ertl G, Alexander RW, Kloner RA (1983) Interactions between coronary occlusion and the renin-angiotensin system in the dog. Basic Res Cardiol 78: 518–533

    Article  PubMed  CAS  Google Scholar 

  42. Ertl G (1987) Coronary vasoconstriction in experimental myocardial ischemia. J Cardiovasc Pharmacol 9 (suppl 2): S9–S17

    Article  PubMed  CAS  Google Scholar 

  43. Fingerle J, Au YPT, Clowes AW, Reidy MA (1990) Intimal lesion formation in rat carotid arteries after endothelial denudation in absence of medial injury. Atherosclerosis 10: 1082–1087

    CAS  Google Scholar 

  44. Fletcher PJ, Pfeffer JM, Pfeffer MA, Braunwald E (1981) Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction: effects on systolic function. Circ Res 49: 618–626

    PubMed  CAS  Google Scholar 

  45. Forrester JS, Fishbein M, Helfant R, Fagin J (1991) A paradigm for restenosis based on cell biology: Clues for the development of new preventive therapies. J Am Coll Cardiol 17: 758–769

    Google Scholar 

  46. Freer RJ, Pappano AJ, Peach MJ, Bing KZ, McLean MJ, Vogel S, Sperelakis N (1976) Mechanism for the positive inotropic effect of angiotensin II on isolated cardiac muscle. Circ Res 39: 178–183

    PubMed  CAS  Google Scholar 

  47. Freeman AP, Walsh WF, Giles BW (1984) Early and long-term results of coronary artery bypass grafting with severely depressed left ventricular performance. Am J Cardiol 54: 749–754

    Article  PubMed  CAS  Google Scholar 

  48. Furchgott RF, Vanhoutte PM (1989) Endothelium-derived relaxing and contracting factors. FASEB J 3: 2007–2010

    PubMed  CAS  Google Scholar 

  49. Gasic S, Dudzcak R, Korn A (1990) ACE inhibition with Cilazapril improves myocardial perfusion to the ischemic regions during exercise: A pilot study. J Cardiovasc Pharmacol 15: 227–232

    Google Scholar 

  50. Gibbs JSR, Crean PA, Mockus L, Wright C, Sutton GC, Fox KM (1989) The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. Br Heart J 62: 112–117

    Article  PubMed  Google Scholar 

  51. Halperin JL, Faxon DP, Creager MA (1982) Coronary hemodynamic effects of angiotensin inhibition by Captopril and teprotide in patients with congestive heart failure. Am J Cardiol 50: 967–972

    Article  PubMed  CAS  Google Scholar 

  52. Heusch G (1990) Alpha-adrenergic mechanisms in myocardial ischemia. Circulation 81: 1–13

    Article  PubMed  CAS  Google Scholar 

  53. Hung J, Kelly DT, Baird DK (1980) Aorto-coronary bypass grafting in patients with severe left ventricular dysfunction. J Thorac Cardiovasc Surg 79: 718–723

    PubMed  CAS  Google Scholar 

  54. Ignarro LJ (1989) Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 65: 1–21

    PubMed  CAS  Google Scholar 

  55. Jawien A, Lindner V, Bowen-Pope DF, Schwartz SM, Reidy MA, Clowes AW (1990) Platelet derived groth factor ( PDGF) stimulates arterial smooth muscle cell proliferation in vivo. FASEB J 4: 342

    Google Scholar 

  56. Jeremy RW, Allmann KC, Bautovitch G, Harris PJ (1989) Patterns of left ventricular dilation during the six months after myocardial infarction. J Am Coll Cardiol 13: 304–310

    Article  PubMed  CAS  Google Scholar 

  57. Jin M, Wilhelm MJ, Lang RE, Unger T, Lindpaintner K, Ganten D (1987) The endogenous tissue renin-angiotensin systems: From molecular biology to therapy. Am J Med 84 (suppl 3A): 28–36

    Article  Google Scholar 

  58. Kannel WB, Dawber TR (1973) Hypertensive cardiovascular disease. The Framingham Study. In: Onesti G, Kim KE, Maya JH, eds. Hypertension: mechanisms and management. New York: Grune and Stratton:93

    Google Scholar 

  59. Kannel WB (1976) Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol 37: 269–282

    Article  PubMed  CAS  Google Scholar 

  60. Keck M (1987) Anti-ischemic effect of captopril in patients with stable angina pectoris. Herz Kreisl 19: 319–321

    Google Scholar 

  61. Kelm M, Schrader J (1988) Nitric oxide release from the isolated guinea pig heart. Eur J Pharmacol 155: 317–321

    Article  PubMed  CAS  Google Scholar 

  62. Kennedy JW, Kaiser GC, Fisher LD (1981) Clinical and angiographic predictors of operative mortality from the Collaberative Study in Coronary Artery Surgery ( CASS ). Circulation 63: 793–802

    Google Scholar 

  63. Khairallah PA (1972) Action of angiotensin on adrenergic nerve endings: Inhibition of norepinephrine uptake. Fed Proc 31: 1351–1357

    PubMed  CAS  Google Scholar 

  64. Kimura E, Hashimoto K, Furukawa S (1973) Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am Heart J 85: 635–647

    Article  PubMed  CAS  Google Scholar 

  65. Kiowski W, Zuber M, Elsasser S, Erne P, Pfisterer M, Burkart F (1991) Coronary vasodilatation and improved myocardial lactate metabolism after angiotensin converting enzyme inhibition with cilazapril in patients with congestive heart failure. Am Heart J 122: 1382–1388

    Article  PubMed  CAS  Google Scholar 

  66. Kirchheim HR, Ehmke H, Hackenthal E (1987) Autoregulation of renal blood flow, glomerular filtration rate and renin release in conscious dogs. Pfliigers Arch 410: 441–449

    Article  CAS  Google Scholar 

  67. Koch-Weser J (1964) Myocardial actions of angiotensin. Circ Res 14: 337–344

    PubMed  CAS  Google Scholar 

  68. Lai C, Onnis E, Orani E (1987) Antiischemic activity of ACE inhibitor enalapril in normotensive patients with stable effort angina. J Am Coll Cardiol 9: 192A

    Google Scholar 

  69. Leimgruber PP, Roubin GS, Hollman J, Cotsonis GA, Meier B, Douglas JS, King SB IE, Gruentzig AR (1986) Restenosis after successful angioplasty in patients with single-vessel disease. Circulation 73: 710–717

    Article  PubMed  CAS  Google Scholar 

  70. Liang CS, Gavras H, Hood B (1978) Renin-angiotensin system inhibition in conscious sodium depleted dogs. Effects on systemic and coronary hemodynamics. J Clin Invest 62: 874–881

    Google Scholar 

  71. Liang CS, Gavras H, Black J (1982) Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation 66: 1249–1255

    Google Scholar 

  72. Li K, Chen X (1987) Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat. J Mol Cell Cardiol 19: 909–915

    Article  PubMed  CAS  Google Scholar 

  73. Limas CJ (1974) Stimulation by angiotensin of myocardial prostaglandins. Biochim Biophys Acta 337: 417–420

    PubMed  CAS  Google Scholar 

  74. Lindpaintner K, Ganten D (1991) The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 68: 905–920

    Google Scholar 

  75. Linz W, Schölkens BA, Manwen J (1986) The heart as a target for converting enzyme inhibitors: Studies in ischaemic isolated working rat hearts. J Hypertension 4 (suppl 6): S477–S479

    CAS  Google Scholar 

  76. Linz W, Schölkens BA, Yi-Fan Han (1986) Beneficial effects of the converting enzyme inhibitor ramipril in ischemic hearts. J Hypertens 8 (suppl 10): S91–S99

    CAS  Google Scholar 

  77. Linz W, Schólkens BA (1987) Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts. J Cardiovasc Pharmacol 10 (suppl 7): S75–S82

    Article  PubMed  CAS  Google Scholar 

  78. Linz W, Schölkens BA, Kaiser J (1989) Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril. Cardiovasc Drugs Ther 3: 873–882

    Article  PubMed  CAS  Google Scholar 

  79. Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM (1990) PDGF ligand and receptor gene expression during repair ligand. J Cell Biol 111: 2149–2158

    Article  PubMed  CAS  Google Scholar 

  80. McAlpine HM, Morton JJ, Leckie B, Dargie HJ (1987) Use of oral ACE-inhibitors post infarct. J Cardiovasc Pharmacol 9 (suppl 2): S25–S30

    Article  PubMed  CAS  Google Scholar 

  81. McKay RG, Pfeffer MA, Pasternak RC (1986) Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 74: 693–702

    Article  PubMed  CAS  Google Scholar 

  82. MERCATOR Study Group (1992) Does the new angiotensin converting enzyme inhibitor Cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation 86: 100–110

    Google Scholar 

  83. Mettauer B, Rouleau J-L, Daly P (1986) The effect of Captopril on the coronary circulation and myocardial metabolism of patients with coronary artery disease. Postgrad Med J 62 (suppl 1): 54–58

    PubMed  Google Scholar 

  84. Michorowski B, Ceremuzynski L (1983) The renin-angiotensin-aldosterone system and the clinical course of acute myocardial infarction. Eur Heart J 4: 259–264

    PubMed  CAS  Google Scholar 

  85. Mulligan IP, Fraser AG, Lewis MJ, Henderson AH (1989) Effects of enalapril on myocardial noradrenaline overflow during exercise in patients with chronic heart failure. Br Heart J 61: 23–28

    Article  PubMed  CAS  Google Scholar 

  86. Naftilan AJ, Pratt RE, Dzau VJ (1989) Induction of platelet derived groth factor A chain and C-myc gene expressions by angiotensin II in culture rat vascular smooth muscle cells. J Clin Invest 83: 1419–1424

    Article  PubMed  CAS  Google Scholar 

  87. Needleman P, Marshall GR, Sobel BE (1975) Hormone interactions in the isolated rabbit heart. Synthesis and coronary vasomotor effects of prostaglandins, angiotensin and bradykinin. Circ Res 37: 802–808

    Google Scholar 

  88. Palmer RMJ, Ferrige AG, Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524–526

    Article  PubMed  CAS  Google Scholar 

  89. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE (1990) Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323: 22–27

    Article  PubMed  CAS  Google Scholar 

  90. Pfeffer JM, Pfeffer MA, Braunwald E (1985) Influence of chronic Captopril therapy on the infarcted left ventricle of the rat. Circ Res 57: 84–95

    PubMed  CAS  Google Scholar 

  91. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P (1985) Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with Captopril. Circulation 72: 406–412

    Article  PubMed  CAS  Google Scholar 

  92. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E (1988) Effect of Captopril on progressive ventricular dilatation after myocardial infarction. N Engl J Med 319: 80–86

    Article  PubMed  CAS  Google Scholar 

  93. Pfeffer MA, Braunwald E (1990) Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 81: 1161–1172

    Article  PubMed  CAS  Google Scholar 

  94. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E (1991) Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 260: H1406–H1414

    PubMed  CAS  Google Scholar 

  95. Pfeffer MA, Braunwald E, et al. (1992) Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327: 669–677

    Article  PubMed  CAS  Google Scholar 

  96. Poulsen K, Poulsen LL (1971) Simultaneous determination of plasma converting enzyme and angiotensinase activity by radioimmunoassay. Clin Sci 40: 443–449

    PubMed  CAS  Google Scholar 

  97. Powell JS, Clozel JP, Müller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR (1989) Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245: 186–188

    Article  PubMed  CAS  Google Scholar 

  98. Rietbrock N, Thürmann P, Kirsten R (1988) Anti-ischeamic effect of enalapril in coronary heart disease. A randomized placebo-controlled double blind trial on 12 patients. Dtsch Med Wschr 113: 300–302

    Article  PubMed  CAS  Google Scholar 

  99. Rochette L, Ribuot C, Belichard P (1987) Protective effect of angiotensin converting enzyme inhibitors (CEI): Captopril and perindopril on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion in rat. Clin Exp Theory and Practice A9: 365–368

    Google Scholar 

  100. Roth RH (1972) Action of angiotensin on adrenergic nerve endings: Enhancement of norepinephrine biosynthesis. Fed Proc 31: 1358–1364

    PubMed  CAS  Google Scholar 

  101. Rouleau J-L, Chatteijee K, Benge W, Pärmley WW, Hiramatsu B (1982) Alterations in left ventricular function and coronary hemodynamics with Captopril, hydralazine and prazosin in chronic ischemic heart failure: A comparative study. Circulation 65: 671–678

    Google Scholar 

  102. Rousseau MF, Close P, Pouleur H (1989) Are the angiotensin-converting enzyme inhibitors poor anti-ischemic drugs? Circulation 80 (suppl II):II52

    Google Scholar 

  103. Rubio R, Berne RM (1969) Release of adenosine by the normal myocardium and its relationship to the regulation of coronary resistance. Circ Res 25: 407–412

    PubMed  CAS  Google Scholar 

  104. Schölkens BA, Linz W, Koenig W (1988) Effects of the angiotensin converting enzyme inhibitor ramipril in isolated ischemic rat heart are abolished by a bradykinin antagonist. J Hypertens 6: S25–S28

    Article  Google Scholar 

  105. Schoenberger JA (1988) Emerging benefits of angiotensin converting enzyme inhibitors versus other antihypertensive agents. Am J Med 84 (suppl 4A): 30–35

    Article  PubMed  CAS  Google Scholar 

  106. Schwartzkopff B, Vogt M, Knauer S, Motz W, Strauer BE (1991) Medial hypertrophy of intramural coronary arteries in patients with reduced coronary reserve in hypertensive heart disease. Circulation 84 (suppl II): II–479

    Google Scholar 

  107. Scott-Burden T, Resink TJ, Hahn AW, Bühler FR (1990) Induction of thrombospondin expression in vascular smooth muscle cells by angiotensin II. J Cardiovasc Pharmacol 16 (suppl 7): 17–20

    Google Scholar 

  108. Serruys PW, Luijten HE, Beatt KJ, Geuskens R,, de Feyter PJ et al. (1988) Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon: A quantitative angiographic study in 342 consecutive patients at 1, 2, 3 and 4 months. Circulation 77: 361–371

    Article  PubMed  CAS  Google Scholar 

  109. Sharpe N (1991) Angiotensin-converting enzyme inhibitors in heart failure: a role after myocardial infarction. J Cardiovasc Pharmacol 18 (suppl 2): S99–S104

    PubMed  Google Scholar 

  110. The SOLVD Investigators (1990) Studies of left ventricular dysfunction (SOLVD)-rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol 66: 315–322

    Article  Google Scholar 

  111. The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685–691

    Article  Google Scholar 

  112. Starke K, Werner U, Schuermann HJ (1966) Wirkungen von Angiotensin auf Funktion und Noradrenalinabgabe isolierter Kaninchenherzen in Ruhe und bei Sympathikusreizung. Naunyn Schmiedebergs Arch Pharmacol 265: 170–186

    Google Scholar 

  113. Starke K (1971) Action of angiotensin on uptake, release, and metabolism of 14C NE by isolated rabbit hearts. Eur J Pharmacol 14: 112–123

    Article  PubMed  CAS  Google Scholar 

  114. Strauer BE (1990) The significance of coronary reserve in clinical heart disease. J Am Coll Cardiol 15: 775–782

    Article  PubMed  CAS  Google Scholar 

  115. Strozzi C, Cocco G, Portaluppi F, Urso L, Alfrigo R, Rizzo A, Tasini MT, Montanari L, Zannell AH (1987) Ergometric evaluation of the effects of Captopril in hypertensive patients with stable angina. Curr Ther Res 41: 301–304

    Google Scholar 

  116. Strozzi C, Cocco G, Portaluppi F, Urso L, Alfrigo R, Tasini MT, Montanari L, Al Yassini K, Rizzo A (1987) Effects of Captopril on the physical work capacity of nor- motensive patients with stable effort angina. Cardiology 74:226–228,

    Google Scholar 

  117. Swartz SL, Williams GH, Hollenberg NK, Levine L, Denk JR, Moore TJ (1980) Captopril-induced changes in prostaglandin production. J Clin Invest 65: 1257–1264

    Article  PubMed  CAS  Google Scholar 

  118. Swedberg K, Held P, Kjekshus J, et al. (1991) Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 327: 678–684

    Article  Google Scholar 

  119. Tardieu A, Virot P, Vandroux JC (1986) Effects of Captopril on myocardial perfusion in patients with coronary insufficiency: Evaluation by the exercise test and quantitative myocardial tomoscintigraphy using thallium-201. Postgrad Med J 62 (suppl 1): 38–41

    PubMed  Google Scholar 

  120. Unger T, Gohlke P, Paul M, Rettig R (1991) Tissue renin-angiotensin system: Fact or fiction? J Cardiovasc Pharmacol 18 (suppl 2): 20–28

    Google Scholar 

  121. Unterberg C, Buchwald A, Vogt A (1990) Akute Effekte des Angiotensin-Converting-Enzym-Hemmers Ramipril bei Patienten mit koronarer Herzerkrankung. Med Klin 85: 78–81

    CAS  Google Scholar 

  122. van Gilst WH, de Graeff PA, Kingma JH (1984) Captopril reduces purine loss and reperfusion arrhythmias in the rat heart after coronary artery occlusion. Eur J Pharmacol 100: 113–117

    Article  PubMed  Google Scholar 

  123. van Gilst WH, de Graeff PA, Wesseling H (1986) Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of Captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol 8: 722–728

    Google Scholar 

  124. Van Gilst WH, Scholtens E, de Graeff PA (1988) Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation. Circulation 77 (suppl I): I24–129

    Google Scholar 

  125. Vanhoutte PM, Auch-Schwelk W, Biondi ML, Lorenz RR, Schini VB, Vidal MJ (1989) Why are converting enzyme inhibitors vasodilators? Br J Clin Pharmacol 28: 95S–104S

    PubMed  CAS  Google Scholar 

  126. Vogt M, Ulbricht JU, Motz W (1988) Lack of evidence for antianginal effects of enalapril. Circulation 78 (suppl II): II–328

    Google Scholar 

  127. Vogt M, Motz W, Strauer BE (1989) Coronary flow reserve in arterial hypertension. Scand J Clin Lab Invest 49 (suppl): 196: 7–14

    CAS  Google Scholar 

  128. Vogt M, Motz W, Pölitz B, Scheler S, Strauer BE (1991) Improvement of coronary reserve by chronic treatment with ACE-inhibitors. Circulation 84 (suppl II): 11–136

    Google Scholar 

  129. Waeber B, Nussberger J, Brunner HR (1990) Angiotensin converting enzyme inhibition in arterial hypertension. Wien Med Wschr 1 /2: 22–29

    Google Scholar 

  130. Webster WM, Fitzpatrick MA, Nicholls MG, Ikram H, Wells JE (1985) Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 56: 566 - 569

    Article  PubMed  CAS  Google Scholar 

  131. Wenting GJ, Man int Veld AJ, Woittiez AJ, Derkx FH, Schalekamp AD (1984) Captopril in the treatment of severe acute and chronic heart failure. Progr Pharmacol 5: 107–114

    Google Scholar 

  132. Wesseling H, De Graeff PA, Van Gilst WH, Kingma JH, de Langen CDJ (1989) Cardiac arrhythmias: A new indication for angiotensin-converting enzyme inhibitors. J Hum Hypertens 3: 89–95

    Google Scholar 

  133. Westfall TC (1977) Local regulation of adrenergic neurotansmission. Physiol Rev 57: 659–729

    PubMed  CAS  Google Scholar 

  134. Westlin W, Mullane K (1988) Does Captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals? Circulation 77 (suppl I):I–30–1–34

    Google Scholar 

  135. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ (1987) Left ventricular end-systolic as the major determinant of survival after recovery from myocardial infarction. Circulation 76: 44–51

    Article  PubMed  CAS  Google Scholar 

  136. Yanagisawa M, Kurihara H, Kimura S (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 331: 411–416

    Article  Google Scholar 

  137. Yang HYT, Erdös EG (1967) Second kininase in human blood plasma. Nature 215: 1402–1403

    Article  PubMed  CAS  Google Scholar 

  138. Yang HYT, Erdös EG, Levin Y (1971) Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J Pharmacol Exp Ther 177: 291–300

    PubMed  CAS  Google Scholar 

  139. Young MA, Vatner SF (1986) Regulation of large coronary arteries. Circ Res 59: 579–585

    PubMed  CAS  Google Scholar 

  140. Zannad F, Gilgenkrantz JM (1989) ACE inhibitors in hypertension: A European viewpoint. Cardiology 76 (suppl 12): 31–41

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiology, Pneumology and Angiology, Heinrich-Heine-University of Düsseldorf, Moorenstr. 5, D-4000, Düsseldorf 1, Germany

    Dr. med. Martin Vogt, W. Motz & B. E. Strauer

  2. Medizinische Klinik und Poliklinik B Abteilung für Kardiologie, Pneumologie und Angiologie, der Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, D-4000, Düsseldorf 1, Germany

    Dr. med. Martin Vogt

Authors
  1. Dr. med. Martin Vogt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Motz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. E. Strauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Pharmakologie, der Universitä Regensburg, Universitätsstraße 31, 8400, Regensburg, Germany

    H. Grobecker

  2. Abt. Pathophysiologie Zentrum Innere Medizin, Universitätsklinikum Essen, Hufelandstraße 55, 4300, Essen, Germany

    Gerd Heusch

  3. Abt. für Kardiologie, Pneumologie, Med. Klinik und Poliklinik B der Heinrich-Heine-Universität, Moorenstraße 5, 4000, Düsseldorf 1, Germany

    B. E. Strauer

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt

About this chapter

Cite this chapter

Vogt, M., Motz, W., Strauer, B.E. (1993). ACE-inhibitors in coronary artery disease?. In: Grobecker, H., Heusch, G., Strauer, B.E. (eds) Angiotensin and the Heart. Steinkopff. https://doi.org/10.1007/978-3-642-72497-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72497-8_4

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-7985-0936-8

  • Online ISBN: 978-3-642-72497-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation